-Bloomberg
JMP Securities Maintains Market Outperform on Evelo Biosciences, Lowers Price Target to $41.5
JMP Securities analyst Gobind Singh maintains Evelo Biosciences (NASDAQ:EVLO) with a Market Outperform and lowers the price target from $44 to $41.5.